STAT3 and neoplasm: PIAS3 is an endogenous inhibitor of STAT3 through prohibiting its DNA binding, and the loss of PIAS3 in cancers contributes to enhanced STAT3 activity and subsequent tumor growth, as well as impacts patient survival, identifying PIAS3 a promising therapeutic target12,31–33.